Demerol Meperidine Market Analysis

Global Demerol Meperidine Market Overview

The Demerol Meperidine Market Size was valued at USD 0.4 Billion in 2022 and is projected to grow from USD 0.64 Billion in 2023 to USD 1.8 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.51% during the forecast period (2023 - 2032).The cost efficiency of OTC analgesics drugs, technological advancement in the field of drug delivery systems, increasing awareness amongst patients, effective pain management solutions across various medical conditions, medical recommendations, patient history, and potential dangers are only a few of the variables that affect healthcare practitioners' decisions regarding the prescription of opioids, are the key market drivers enhancing the market growth.

Demerol Meperidine Market Trends

Cost efficiency of OTC analgesics drugs is driving the market growth

The over-the-counter (OTC) analgesic market segment has grown and maintained its appeal due in large part to the cost effectiveness of these medications. OTC analgesics, which are widely available to consumers without a prescription and include acetaminophen, ibuprofen, and aspirin, are non-prescription drugs. These medications' accessibility and pricing have significantly influenced consumer behavior and healthcare decisions.

OTC analgesics offer a cost-effective alternative for people seeking relief from pain and discomfort compared to prescription drugs, which can require consultation fees, doctor visits, and higher drug pricing. This factor is especially important for people with limited healthcare coverage, high deductibles, or those looking for quick pain relief without the cost of prescription medications.

Consumers save time and money by choosing to buy OTC analgesics without a prescription since it is more convenient. OTC analgesics are easily accessible at pharmacies, grocery stores, and online platforms, allowing people to manage their pain without having to make appointments with doctors or wait in line for hours at hospitals. This accessibility gives people the power to manage their own healthcare and quickly relieve discomfort, which lowers the overall cost of healthcare-related spending.

The accessibility of over-the-counter analgesics fits with the growing emphasis on self-management and preventative healthcare around the world. Consumers are looking for solutions that are both efficient and affordable as they adopt a more proactive approach to health and wellbeing. OTC analgesics take advantage of this trend by providing a variety of alternatives that may be tailored to varied pain levels and preferences without putting a strain on a person's budget. Additionally, the affordability of over-the-counter analgesics is helpful for advancing public health objectives. Healthcare systems can lessen the strain on medical facilities and cut down on the number of unneeded doctor visits for minor ailments by promoting the usage of economic pain management choices. This redistribution of medical resources enables people to autonomously manage common pain disorders while allowing medical professionals to focus on more urgent cases. Thus, driving the Demerol Meperidine market revenue.

Demerol Meperidine Market Segment Insights:

Demerol Meperidine Product Type Insights

The Market segments of Demerol Meperidine, based on Product Type, includes Parenteral and Tablets. The parenteral segment dominated the market in 2022. Parenteral intravenous (IV) injection provides a rapid beginning of action, which is critical for successfully treating acute and severe pain. Furthermore, parenteral administration is widely used in hospitals and clinics where medical professionals can ensure accurate dosage and close monitoring of the patient's response. Patients Unable to Take Oral medicines: Patients who are unable to take oral medicines due to situations including post-surgical recovery, nausea, or digestive issues may find parenteral Demerol to be useful.

Figure 1: Demerol Meperidine Market, by product type, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Demerol Meperidine Application Insights

The Demerol Meperidine Market segmentation, based on Application, includes Pain Relief, Anesthesia, Cough Suppression, Diarrhea Suppression and De-addiction. The pain relief category generated the most income in 2022. The demand for efficient pain management pharmaceuticals is driven by the prevalence of acute and chronic painful disorders, such as post-operative pain, injury-related pain, cancer-related pain, and chronic illnesses.

Demerol Meperidine Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Demerol Meperidine Market dominated this market in 2022 (45.80%). One of the greatest rates of chronic pain syndromes are found in North America. The American Pain Society estimates that 50 million adults in the US deal with chronic pain. Meperidine is a popular analgesic for people with chronic pain. Further, the U.S. market of Demerol Meperidine held the largest market share, and the Canada market of Demerol Meperidine was the fastest growing market in the North America region.

Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: DEMEROL MEPERIDINE MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Demerol Meperidine market accounts for the second-largest market share. The rise in surgical operations is a key element driving the meperidine market in Europe. In 2020, there will likely be 20 million surgical procedures in Europe, according to the European Society of Anesthesiology. Meperidine is a typical anesthetic used in many surgical operations. Further, the German market of Demerol Meperidine held the largest market share, and the UK market of Demerol Meperidine was the fastest growing market in the European region.

The Asia-Pacific Demerol Meperidine Market is expected to grow at the fastest CAGR from 2023 to 2032. In Asia Pacific, demand for potent painkillers like Demerol is being driven by rising healthcare awareness and a greater focus on pain treatment. The demand for appropriate painkillers may increase as people become more aware of their healthcare options. Moreover, China’s market of Demerol Meperidine held the largest market share, and the Indian market of Demerol Meperidine was the fastest growing market in the Asia-Pacific region.

Demerol Meperidine Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Demerol Meperidine market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Demerol Meperidine industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the market of Demerol Meperidine to benefit clients and increase the market sector. In recent years, the Demerol Meperidine industry has offered some of the most significant advantages to medicine. Major market players in the Demerol Meperidine, including Actavis PLC, Sun Pharmaceuticals, Sanofi, Boehringer Ingelheim, Pfizer, Inc., Janssen Pharmaceuticals, Inc., Egalet Corporation, Mallinckrodt Pharmaceuticals, Purdue Pharma, Endo Pharmaceuticals Inc. and others, are attempting to increase market demand by investing in research and development operations.

Sun Pharmaceutical Industries Ltd. (Sun Pharma), a specialty pharmaceutical company, offers a variety of pharmaceutical formulations, including branded generics and generic medications. The company's product line includes items for the treatment of cardiac issues as well as mental, neurological, nephrological, gastroenterological, orthopedic, and ophthalmologic diseases and disorders. The company makes over-the-counter medicines, active pharmaceutical ingredients (APIs), and complicated formulations. Additionally, it carries out process chemistry. In addition to liquids, ointments, creams, injectables, tablets, capsules, and injectables, it also offers pharmaceuticals in a variety of dosing formats. The company has production facilities in a number of regions, including North America, Latin America, the EMEA region, and Asia Pacific. Sun Pharma's corporate headquarters are in Mumbai, Maharashtra, India.

Sanofi is a healthcare company that is engaged in the creation, manufacturing, distribution, and discovery of several medications and vaccines. Additionally, it sells human immunizations for protection against a variety of bacterial and viral illnesses, as well as multiple sclerosis and cancer treatments and other items. In addition, the business offers products for women's health, digestion, allergy, cough, cold, flu, and sinus infections, pain, as well as vitamins, minerals, and supplements. Sanofi's research and development efforts are primarily focused on creating combination therapies to increase treatment efficacy and on creating novel biologic formulations to produce precision medicines. It operates in the Americas, Europe, Asia-Pacific, Middle East, and Africa. Sanofi's corporate headquarters are in Paris, Ile-de-France, France.

Key Companies in the Demerol Meperidine market include

• Actavis PLC


• Sun Pharmaceuticals


• Sanofi


• Boehringer Ingelheim


• Pfizer, Inc.


• Janssen Pharmaceuticals, Inc.


• Egalet Corporation


• Mallinckrodt Pharmaceuticals


• Purdue Pharma


• Endo Pharmaceuticals Inc.

Demerol Meperidine Industry Developments

August 2023: Sanofi announced its plans to enter into a partnership with Hanmi Pharmaceutical Co to develop the GLP-1 class Epeglenatide.

July 2023: Sanofi entered into a strategic collaboration with Recludix Pharma to develop and commercialize first-in-class oral small molecule STAT6 inhibitors for patients with immunological and inflammatory diseases.

July 2023: Endo Pharmaceuticals launched a bivalirudin injection in a ready-to-use 250 mg/50 mL single-use vial.

June 2023: Endo Pharmaceuticals launched PREVDUO (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe.

Demerol Meperidine Market Segmentation

Demerol Meperidine Product Type Outlook

• Parenteral


• Tablets

Demerol Meperidine Application Outlook

• Pain Relief


• Anesthesia


• Cough Suppression


• Diarrhea Suppression


• De-addiction

Demerol Meperidine Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  
  


•  Latin America